Atacand (Candesartan) Real Life Study
- Registration Number
- NCT00620178
- Lead Sponsor
- AstraZeneca
- Brief Summary
This study is a Swedish historical cohort study in patients prescribed Atacand or Cozaar for hypertension by selected primary care centres. Data will be extracted anonymously from electronic medical records. In addition, data regarding morbidity and mortality will be collected by merging the cohort with the following national registries: the Hospital Discharge Register (Slutenvårdsregistret), the Cause of Death Register and the Heart Intensive Care Admission (RIKS-HIA)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 14000
Inclusion Criteria
- Recorded blood pressure prior to therapy of > 140 and/or 90 mmHg
- Diagnosed as hypertensive within 15 months
- First prescription of Cozaar or Atacand between 1 January 1999 and 31 December 2007, inclusive
Exclusion Criteria
- Previous prescription within 15 months any drug from the ATC groups C02, C03, C07 - C09 inclusive
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description 1 Candesartan Cilexetil Candesartan 2 Losartan Losartan
- Primary Outcome Measures
Name Time Method The primary efficacy objective is to investigate, on basis of 'first to event', the development of new cardiovascular diseases (CVD). 1999 - 2007
- Secondary Outcome Measures
Name Time Method Cardiovascular disease states and procedures in the background and over the entire observation period will be identified by use of ICD-9 and ICD-10 coding for diseases of the cardiovascular system. Specifically are death, acute cardiovascular events, new 1999 - 2007 Health care consumption will be assessed as contacts with health care providers, in-hospital time periods for cardiovascular disease states with associated therapeutic procedures, and times spent within various levels of care (e.g. ICU and general ward). 1999 - 2007
Trial Locations
- Locations (1)
Research Site
🇸🇪Uppsala, Sweden